Six mice were assigned per dose group.
When the tumors grew 12 13 mm in diameter, the mice were assigned to the control (n = 5) and sorafenib-treated (n = 5) groups.
The A498 xenograft was established in nude mice, and the mice were assigned to the control (n = 5) and treatment (n = 5) groups.
For in vivo PK testing, a total of 48 male C57BL/6 mice were randomly divided into two groups (n = 24 per group), and 3 mice were assigned to each pharmacokinetic time point.
In a second experiment, drug-naïve mice were assigned to one of four treatment groups: saline + saline, saline + ethanol (1.78 g/kg), taurine (1.78 g/kg) + saline, or ethanol + taurine.
For animal experiments, 10 mice were assigned per treatment group.
Fourteen days after transplantation of BCR-ABL-expressing donor cells, or when tumor was measurable (100 120 mm3 size), mice were assigned randomly and received treatment indicated.
Next, mice were assigned to a devalued or non-devalued group by matching the number of reinforcers earned during instrumental training.
Following a positive urine test, mice were assigned to the diabetic groups (n = 10) or, those with negative urine test that were injected with vehicle, to control groups (n = 10).
Trypan blue staining confirmed viable STS cells (SKLMS1 and HT1080 1×106/0.1 mL HBSS/mouse) were injected subcutaneously into the flank of six week old female SCID mice (n = 20/experiment), growth was measured twice weekly; after establishment of palpable lesions mice were assigned to two treatment groups (10 mice per group): control (vehicle only) and WFA, i.p. (2 mg/kg/day).
Six mice were assigned for each experiment.
